Search | IOVS | ARVO Journals

Showing 1 – 20 of 67

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Retina December 2024

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

PDF

Kim Lien Huber; Heiko Stino; Irene Steiner; Philipp Fuchs; Felix Goldbach; Julia Mai; Bianca S. Gerendas; Katharina Kriechbaum; Ursula Schmidt-Erfurth; Andreas Pollreisz
TAGS: aflibercept, diabetic macular edema, eye, faricimab, injections, visual acuity
Invest. Ophthalmol. Vis. Sci.. 2024; 65(14):46. https://doi.org/10.1167/iovs.65.14.46

Includes: Supplemental Content

ARVO Annual Meeting Abstract June 2024

10-year follow-up of patients with central serous chorioretinopathy

Johannes Iby; Wolf Bühl; Judith Kreminger; Bianca S Gerendas; Alice R Motschi; Michael Pircher; Ursula Schmidt-Erfurth; Stefan Sacu

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6631.

ARVO Annual Meeting Abstract June 2024

The RAP study, Report 7: The worldwide distribution of macular neovascularization type 3: A country and region-based analysis

Bilal Haj Najeeb; Bianca S Gerendas; Gabor Gy Deak; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):2318.

ARVO Annual Meeting Abstract June 2023

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Jennifer I Lim; Shih-Jen Chen; Nathan Steinle; Glenn J Jaffe; Bianca S Gerendas; Francis Abreu; Acner Camino; Kara Gibson; Nitin Jain; Eugene Shildkrot; Audrey Souverain; Yannan Tang; Jeffrey Willis; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2815.

ARVO Annual Meeting Abstract June 2023

Correlation between manually measured macular fluid height and automatic quantification of macular fluid volume in nAMD

Stefan Steiner; Bianca S Gerendas; Gabor Deak; Martin Michl; Gregor Sebastian Reiter; Oliver Leingang; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4330.

ARVO Annual Meeting Abstract June 2023

Ability of eye-care professionals in grading retinal fluid volumes and change in age-related macular degeneration assessed by automated fluid monitoring

Martin Michl; Bianca S Gerendas; Anastasiia Gruber; Philipp Seeboeck; Felix Goldbach; Georgios Mylonas; Oliver Leingang; Wolf Bühl; Stefan Sacu; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2167.

ARVO Annual Meeting Abstract June 2023

Concordance of OCT and FA-based MNV classifications in neovascular AMD and correlation with fluid volumes

Gabor Deak; Bianca S Gerendas; Georgios Mylonas; Guenther Weigert; Martin Michl; Felix Goldbach; Oliver Leingang; Irene Steiner; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):288.

ARVO Annual Meeting Abstract June 2023

Development of Fibrosis and Atrophy in nAMD in regard to fluid volume (IRF, SRF, PED) and fluctuation localization (1, 3, 6mm)

Guenther Weigert; Gabor Deak; Martin Michl; Gregor Sebastian Reiter; Daniela Boryshchuk; Florian Frommlet; Stefan Sacu; Bianca S Gerendas; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):917.

ARVO Annual Meeting Abstract June 2023

Human Expert Grading versus Automated Quantification of Fluid Volumes in nAMD, DME and BRVO

Felix Goldbach; Bianca S Gerendas; Oliver Leingang; Thomas Alten; Jonas Brugger; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):1286.

ARVO Annual Meeting Abstract June 2023

Protocol T-Retreatment based on CST and BCVA stability: can we do better considering intraretinal fluid volumes for disease stability?

Bianca S Gerendas; Oliver Leingang; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2634.

ARVO Annual Meeting Abstract June 2023

Correlation between retinal fluid volumes and macular neovascularization parameters in neovascular AMD

Markus Schranz; Bianca S Gerendas; Gregor Sebastian Reiter; Hrvoje Bogunovic; Gabor Deak; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):4425.

ARVO Annual Meeting Abstract June 2022

Comparison of diabetic retinopathy severity scores and landmark measurements from ultra-widefield cameras to the gold standard of 7-field color fundus photography

Bianca S Gerendas; Anastasia Matakova; Felix Goldbach; Astrid Jakob; Jonas Brugger; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):1012 – F0259.

ARVO Annual Meeting Abstract June 2022

Comparison of a human versus deep learning-based evaluation of fluid change in real-world OCT images of neovascular AMD

Martin Michl; Bianca S Gerendas; Philipp Seeböck; Elisa de Llano; Anastasiia Gruber; Felix Goldbach; Georgios Mylonas; Oliver Leingang; Wolf Bühl; Stefan Sacu; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3354 – F0163.

ARVO Annual Meeting Abstract June 2022

The RAP study, Report 6: Quantification of exudative biomarkers in neovascular age-related macular degeneration (nAMD) using deep learning, a type-based comparative analysis.

Bilal Haj Najeeb; Bianca S Gerendas; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3861.

ARVO Annual Meeting Abstract June 2022

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Caroline R Baumal; John Kitchens; Glenn Jaffe; Bianca S Gerendas; Francis Abreu; Kemal Asik; Acner Camino; Nitin Jain; Zdenka Haskova

Invest. Ophthalmol. Vis. Sci.. 2022; 63(7):3851.

ARVO Annual Meeting Abstract June 2021

Quantifying the clinical evaluation of retinal fluid change in real-world OCT images using deep learning

Martin Michl; Felix Goldbach; Georgios Mylonas; Gabor Deak; Thomas Alten; Stefan Sacu; Hrvoje Bogunovic; Bianca S Gerendas; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2455.

ARVO Annual Meeting Abstract June 2021

Deep learning-based automated fluid quantification in clinical routine OCT images in neovascular AMD over 5 years

Bianca S Gerendas; Amir Sadeghipour; Martin Michl; Felix Goldbach; Georgios Mylonas; Thomas Alten; Oliver Leingang; Stefan Sacu; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):122.

ARVO Annual Meeting Abstract June 2021

Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen

Christoph Grechenig; Gregor Sebastian Reiter; Sophie Riedl; Jennifer Arnold; Robyn H Guymer; Bianca S Gerendas; Hrvoje Bogunovic; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):104.

ARVO Annual Meeting Abstract June 2021

Impact of baseline vitreomacular interface status on the treatment choice between aflibercept, bevacizumab or ranibizumab for diabetic macular edema

Felix Goldbach; Georgios Mylonas; Bilal Haj Najeeb; Gabor Deak; Martin Michl; Jonas Brugger; Bianca S Gerendas; Ursula Schmidt-Erfurth

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):1040.

ARVO Annual Meeting Abstract June 2021

The RAP study, Report 4: Discoloration of the macular region in patients with macular neovascularization type 3

Bilal Haj Najeeb; Gabor Deak; Ursula Schmidt-Erfurth; Bianca S Gerendas

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):340.

1 2 3 4

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Filters

Specify Date Range

Real-World Outcomes After Switch From Aflibercept to Faricimab in Eyes With Diabetic Macular Edema

10-year follow-up of patients with central serous chorioretinopathy

The RAP study, Report 7: The worldwide distribution of macular neovascularization type 3: A country and region-based analysis

Durable vision gains and greater fluid control with extended faricimab dosing vs aflibercept in patients with DME

Correlation between manually measured macular fluid height and automatic quantification of macular fluid volume in nAMD

Ability of eye-care professionals in grading retinal fluid volumes and change in age-related macular degeneration assessed by automated fluid monitoring

Concordance of OCT and FA-based MNV classifications in neovascular AMD and correlation with fluid volumes

Development of Fibrosis and Atrophy in nAMD in regard to fluid volume (IRF, SRF, PED) and fluctuation localization (1, 3, 6mm)

Human Expert Grading versus Automated Quantification of Fluid Volumes in nAMD, DME and BRVO

Protocol T-Retreatment based on CST and BCVA stability: can we do better considering intraretinal fluid volumes for disease stability?

Correlation between retinal fluid volumes and macular neovascularization parameters in neovascular AMD

Comparison of diabetic retinopathy severity scores and landmark measurements from ultra-widefield cameras to the gold standard of 7-field color fundus photography

Comparison of a human versus deep learning-based evaluation of fluid change in real-world OCT images of neovascular AMD

The RAP study, Report 6: Quantification of exudative biomarkers in neovascular age-related macular degeneration (nAMD) using deep learning, a type-based comparative analysis.

Personalized treatment interval (PTI) dosing dynamics over 2 years in the phase 3 YOSEMITE and RHINE trials of faricimab in diabetic macular edema

Quantifying the clinical evaluation of retinal fluid change in real-world OCT images using deep learning

Deep learning-based automated fluid quantification in clinical routine OCT images in neovascular AMD over 5 years

Impact of Residual Subretinal Fluid Volumes on Treatment Outcomes in a SRF-tolerant Treat & Extend Regimen

Impact of baseline vitreomacular interface status on the treatment choice between aflibercept, bevacizumab or ranibizumab for diabetic macular edema

The RAP study, Report 4: Discoloration of the macular region in patients with macular neovascularization type 3

To View More...

You must be signed into an individual account to use this feature.